Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

GKOS

Glaukos Corporation

May 17 • 04:00PM ET

109.79

Dollar change -0.62
Percentage change -0.56	%

Healthcare • Medical Devices • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VB VXF VBK IJT IWO IHI SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.88	Insider Own	3.68%	Shs Outstand	49.12M	Perf Week	-0.61%
Market Cap	5.53B	Forward P/E	-	EPS next Y	-1.29	Insider Trans	-25.69%	Shs Float	48.51M	Perf Month	15.41%
Income	-140.87M	PEG	-	EPS next Q	-0.51	Inst Own	103.02%	Short Float	7.24%	Perf Quarter	18.53%
Sales	326.43M	P/S	16.94	EPS this Y	3.40%	Inst Trans	1.34%	Short Ratio	6.81	Perf Half Y	67.18%
Book/sh	9.04	P/B	12.14	EPS next Y	40.97%	ROA	-14.78%	Short Interest	3.51M	Perf Year	84.00%
Cash/sh	5.42	P/C	20.27	EPS next 5Y	8.00%	ROE	-29.37%	52W Range	54.38 - 113.97	Perf YTD	38.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-49.95%	ROI	-16.89%	52W High	-3.67%	Beta	1.09
Dividend TTM	-	Quick Ratio	4.68	Sales past 5Y	12.76%	Gross Margin	77.86%	52W Low	101.89%	ATR (14)	3.95
Dividend Ex-Date	-	Current Ratio	5.38	EPS Y/Y TTM	1.43%	Oper. Margin	-34.26%	RSI (14)	64.28	Volatility	3.28% 4.14%
Employees	907	Debt/Eq	0.85	Sales Y/Y TTM	12.92%	Profit Margin	-43.16%	Recom	1.53	Target Price	112.03
Option/Short	Yes / Yes	LT Debt/Eq	0.85	EPS Q/Q	-13.90%	Payout	-	Rel Volume	0.90	Prev Close	110.41
Sales Surprise	7.56%	EPS Surprise	-21.30%	Sales Q/Q	15.86%	Earnings	May 01 AMC	Avg Volume	515.94K	Price	109.79
SMA20	5.58%	SMA50	13.35%	SMA200	34.51%	Trades		Volume	463,824	Change	-0.56%

Date	Action	Analyst	Rating Change	Price Target Change
May-06-24	Upgrade	Jefferies	Hold → Buy	$84 → $125
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight	$66 → $91
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$65
Nov-28-23	Initiated	Truist	Buy	$88
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$75 → $83
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight	$55 → $80
Dec-22-22	Initiated	Mizuho	Neutral	$48
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral	$48 → $42
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$57
Oct-14-22	Resumed	Stephens	Overweight	$69
Oct-04-22	Initiated	Needham	Buy	$66
Jul-12-22	Upgrade	Stifel	Hold → Buy	$40 → $60
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight	$56
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy	$61
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight	$68
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight	$70
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight	$41
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Jul-14-21	Downgrade	Oppenheimer	Outperform → Perform

Show Previous Ratings

May-14-24 04:47PM	Glaukos Insider Sold Shares Worth $264,791, According to a Recent SEC Filing (MT Newswires)
12:20PM	Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock? (Zacks)
May-02-24 12:01PM	Needham Adjusts Price Target on Glaukos to $113 From $108, Maintains Buy Rating (MT Newswires) +6.19%
11:59AM	JPMorgan Adjusts Price Target on Glaukos to $110 From $108, Maintains Overweight Rating (MT Newswires)
09:14AM	Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
07:12AM	Loading…
07:12AM	Q1 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
03:38AM	Glaukos Corp (GKOS) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic ... (GuruFocus.com)
May-01-24 11:53PM	GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:50PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:35PM	Glaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue Expectations (GuruFocus.com)
04:50PM	Glaukos: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces First Quarter 2024 Financial Results (Business Wire)
Apr-16-24 04:05PM	Glaukos Announces the Release of its 2023 Sustainability Report (Business Wire)
Apr-15-24 08:19AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Apr-12-24 09:22AM	Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally? (Zacks)
07:00AM	Loading…
Apr-10-24 07:00AM	Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1 (Business Wire)
Apr-08-24 10:41AM	Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock? (Zacks)
Apr-04-24 12:02PM	Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS (Zacks)
Apr-03-24 07:00AM	Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant) (Business Wire) +5.40%
Apr-01-24 07:00AM	Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting (Business Wire)
Mar-22-24 11:30AM	Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-13-24 07:56AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Feb-27-24 02:03AM	Glaukos Corp Director Mark Foley Sells 4,560 Shares (GuruFocus.com)
Feb-22-24 10:16AM	Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:58AM	Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
07:47AM	Q4 2023 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-21-24 05:20PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Glaukos Corp (GKOS) Reports Increased Sales but Widening Losses in Q4 and Full Year 2023 (GuruFocus.com)
04:17PM	Glaukos: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
02:04AM	Loading…
Feb-15-24 02:04AM	Insider Sell: Glaukos Corp's President & COO Joseph Gilliam Sells 1,512 Shares (GuruFocus.com)
Feb-14-24 10:00AM	Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Feb-01-24 03:01PM	Glaukos Corp's President & COO Joseph Gilliam Sells 9,476 Shares (GuruFocus.com)
Jan-31-24 07:00AM	Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21 (Business Wire)
Jan-30-24 10:42AM	Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock? (Zacks)
Jan-18-24 07:57PM	Glaukos Corp Insider Sells Company Shares (GuruFocus.com)
Jan-16-24 07:41AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Jan-11-24 11:26AM	Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand (Zacks)
Jan-09-24 07:00AM	Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance (Business Wire) +5.55%
Dec-23-23 01:01AM	Glaukos Corp President & COO Joseph Gilliam Sells 25,000 Shares (GuruFocus.com)
Dec-21-23 01:31AM	Spotify, Salesforce shares gain following upgrades: 4 big analyst picks (Investing.com) +6.92%
Dec-20-23 07:00AM	Glaukos Announces Participation in the J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-23 01:28PM	Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment (Zacks)
Dec-18-23 09:49AM	Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock? (Zacks)
Dec-15-23 05:57AM	Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma (MedTech Dive) +7.58%
Dec-14-23 07:45AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks) +25.36%
07:00AM	Glaukos Announces FDA Approval of iDose TR (travoprost intracameral implant) (Business Wire)
Dec-03-23 10:30AM	Bearish Bets: 3 Stocks You Definitely Should Think About Shorting This Week (TheStreet.com)
Dec-01-23 11:31AM	Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report? (Zacks)
Nov-15-23 08:00AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Nov-07-23 07:00AM	Glaukos Announces Participation in Stifel Healthcare Conference (Business Wire)
Nov-02-23 06:17PM	Glaukos Corporation (NYSE:GKOS) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.58%
10:34AM	Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)
Nov-01-23 07:00PM	Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:07PM	Glaukos Corp (GKOS) Reports 10% Increase in Q3 2023 Net Sales (GuruFocus.com)
04:57PM	Glaukos: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-31-23 07:33AM	Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More (Zacks)
07:00AM	Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-11-23 07:00AM	Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023 (Business Wire)
Oct-05-23 07:53AM	Here's Why You Should Retain Glaukos (GKOS) Stock for Now (Zacks)
Sep-19-23 06:20AM	Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? (Zacks)
Aug-23-23 07:00AM	Glaukos Announces Participation in Wells Fargo Healthcare Conference (Business Wire)
Aug-03-23 11:16AM	Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)
Aug-02-23 10:00PM	Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics (Zacks)
06:05PM	Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:58PM	Glaukos: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 09:02AM	Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS (Zacks)
Jul-31-23 06:05PM	OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-20-23 07:19AM	Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio (Zacks)
Jul-19-23 12:43PM	Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease (Zacks)
Jul-17-23 07:00AM	Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc. (Business Wire)
Jul-14-23 06:22PM	These 2 Soaring Stocks Finished the Week Strong (Motley Fool) +10.40%
08:38AM	Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow? (Zacks)
Jul-12-23 07:00AM	Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023 (Business Wire)
Jun-21-23 08:00PM	GKOS: Lowering target price to $58.00 (Argus Research)
Jun-05-23 07:00AM	Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on) (Business Wire)
May-28-23 10:30AM	Despite currently being unprofitable, Glaukos (NYSE:GKOS) has delivered a 43% return to shareholders over 5 years (Simply Wall St.)
May-24-23 07:00AM	Glaukos Announces Participation in the William Blair Growth Stock Conference (Business Wire)
May-19-23 09:17AM	Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio (Zacks)
May-05-23 04:05PM	Glaukos Announces FDA Acceptance of NDA Submission for iDose TR (Business Wire) +7.75%
May-04-23 07:13AM	Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y (Zacks) +8.85%
May-03-23 06:45PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Glaukos: Q1 Earnings Snapshot (AP Finance)
04:05PM	Glaukos Announces First Quarter 2023 Financial Results (Business Wire)
May-01-23 07:00AM	Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting (Business Wire)
Apr-26-23 08:00PM	GKOS: Lowering target price to $38.00 (Argus Research)
Apr-19-23 07:00AM	Glaukos Announces the Release of its 2022 Sustainability Report (Business Wire)
Apr-17-23 10:50AM	Subdued Growth No Barrier To Glaukos Corporation's (NYSE:GKOS) Price (Simply Wall St.)
Apr-12-23 07:00AM	Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 (Business Wire)
Apr-06-23 05:33AM	Celanese (CE) & Glaukos Join Forces for Glaucoma Treatment (Zacks)
Apr-03-23 11:29AM	Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio (Zacks)
Feb-27-23 07:27AM	Foreign Currency Headwinds Dragged Glaukos Corporation (GKOS) Shares in Q4 (Insider Monkey)
07:00AM	Glaukos Submits New Drug Application to U.S. FDA for iDose TR (Business Wire)
Feb-24-23 05:52AM	Glaukos Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Feb-23-23 10:23AM	Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y (Zacks)
Feb-22-23 05:55PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results (Business Wire)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stapley Marc	Director	May 15 '24	Option Exercise	32.00	6,250	200,000	38,610	May 16 07:45 PM
Stapley Marc	Director	May 15 '24	Sale	112.80	6,250	704,993	32,360	May 16 07:45 PM
Gilliam Joseph E	PRESIDENT & COO	May 10 '24	Option Exercise	55.18	2,395	132,156	104,240	May 14 04:43 PM
Gilliam Joseph E	PRESIDENT & COO	May 10 '24	Sale	110.56	2,395	264,791	101,845	May 14 04:43 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 10 '24	Sale	110.51	353	39,011	51,647	May 14 04:41 PM
Gilliam Joseph E	PRESIDENT & COO	May 06 '24	Option Exercise	55.18	105	5,794	101,950	May 08 05:21 PM
Gilliam Joseph E	PRESIDENT & COO	May 06 '24	Sale	110.36	105	11,588	101,845	May 08 05:21 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 06 '24	Sale	110.26	90	9,923	52,000	May 08 05:08 PM
Gilliam Joseph E	PRESIDENT & COO	May 02 '24	Option Exercise	69.30	2,059	142,689	103,904	May 06 05:23 PM
Gilliam Joseph E	PRESIDENT & COO	May 02 '24	Sale	105.52	2,059	217,263	101,845	May 06 05:23 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	May 02 '24	Sale	105.69	442	46,713	52,090	May 06 05:27 PM
Hoffmeister David F	Director	Apr 10 '24	Option Exercise	7.28	10,000	72,750	15,767	Apr 12 07:49 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 08 '24	Option Exercise	41.69	59,801	2,493,104	161,646	Apr 10 08:20 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 08 '24	Sale	100.47	59,801	6,008,359	101,845	Apr 10 08:20 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 08 '24	Sale	100.54	1,372	137,944	52,532	Apr 09 07:46 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 05 '24	Option Exercise	55.18	2,457	135,577	104,302	Apr 09 07:40 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 05 '24	Sale	96.81	2,457	237,862	101,845	Apr 09 07:40 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 05 '24	Sale	96.63	262	25,316	53,904	Apr 09 07:46 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 04 '24	Option Exercise	55.18	200	11,036	102,045	Apr 05 06:15 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 04 '24	Sale	95.33	434	41,371	54,166	Apr 05 06:13 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 04 '24	Sale	96.57	200	19,314	101,845	Apr 05 06:15 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 03 '24	Option Exercise	55.18	200	11,036	102,045	Apr 05 06:15 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	94.62	316	29,900	54,600	Apr 05 06:13 PM
Gilliam Joseph E	PRESIDENT & COO	Apr 03 '24	Sale	96.61	200	19,322	101,845	Apr 05 06:15 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Apr 02 '24	Sale	90.37	474	42,835	54,916	Apr 03 08:32 PM
Kliman Gilbert H	Director	Mar 07 '24	Option Exercise	32.00	5,000	160,000	35,620	Mar 08 05:12 PM
Kliman Gilbert H	Director	Mar 07 '24	Sale	88.25	5,000	441,250	30,620	Mar 08 05:12 PM
Kliman Gilbert H	Director	Mar 06 '24	Sale	85.34	8,347	712,307	0	Mar 08 05:12 PM
Stapley Marc	Director	Feb 29 '24	Option Exercise	32.00	6,250	200,000	38,610	Mar 04 08:09 PM
Stapley Marc	Director	Feb 29 '24	Sale	90.09	6,250	563,087	32,360	Mar 04 08:09 PM
Kliman Gilbert H	Director	Feb 27 '24	Sale	92.00	8,000	736,000	8,347	Feb 29 05:52 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 23 '24	Option Exercise	39.82	118,831	4,731,666	238,633	Feb 27 09:29 PM
Foley Mark J	Director	Feb 23 '24	Option Exercise	7.28	10,000	72,750	37,780	Feb 26 07:01 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 23 '24	Sale	92.14	140,245	12,922,002	98,388	Feb 27 09:29 PM
Foley Mark J	Director	Feb 23 '24	Sale	92.87	4,560	423,487	33,220	Feb 26 07:01 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 12 '24	Option Exercise	55.18	1,512	83,432	121,314	Feb 14 04:56 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 12 '24	Sale	96.80	1,512	146,362	119,802	Feb 14 04:56 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 09 '24	Option Exercise	55.18	631	34,819	120,433	Feb 12 06:41 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 09 '24	Sale	96.70	631	61,018	119,802	Feb 12 06:41 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 08 '24	Option Exercise	39.10	5,000	195,500	124,802	Feb 12 06:41 PM
Gilliam Joseph E	PRESIDENT & COO	Feb 08 '24	Sale	96.07	5,000	480,350	119,802	Feb 12 06:41 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Feb 08 '24	Sale	95.78	550	52,682	54,035	Feb 09 06:33 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Feb 07 '24	Sale	95.00	33	3,135	54,585	Feb 09 06:33 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 29 '24	Option Exercise	39.10	9,476	370,512	129,278	Jan 31 05:35 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 29 '24	Sale	94.12	9,476	891,881	119,802	Jan 31 05:35 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 22 '24	Option Exercise	39.10	524	20,488	120,326	Jan 24 06:04 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 22 '24	Sale	94.01	524	49,261	119,802	Jan 24 06:04 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jan 18 '24	Sale	90.54	583	52,784	54,618	Jan 22 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 16 '24	Option Exercise	30.92	4,890	151,199	124,692	Jan 18 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 16 '24	Sale	89.17	4,890	436,041	119,802	Jan 18 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 12 '24	Option Exercise	30.92	110	3,401	119,912	Jan 16 04:59 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 12 '24	Sale	89.01	110	9,791	119,802	Jan 16 04:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 09 '24	Option Exercise	7.28	115	837	55,950	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 09 '24	Sale	86.85	115	9,988	55,835	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 08 '24	Option Exercise	7.28	60,000	436,500	115,835	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 08 '24	Sale	82.55	60,000	4,952,706	55,835	Jan 10 07:14 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 02 '24	Option Exercise	7.28	95,000	691,125	150,835	Jan 03 06:18 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 02 '24	Sale	77.20	95,000	7,334,253	55,835	Jan 03 06:18 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 22 '23	Option Exercise	7.28	1	7	55,836	Dec 22 06:03 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 22 '23	Sale	85.32	1	85	55,835	Dec 22 06:03 PM
Gilliam Joseph E	PRESIDENT & COO	Dec 21 '23	Option Exercise	41.69	25,000	1,042,250	145,001	Dec 22 06:05 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 21 '23	Option Exercise	7.28	79,684	579,701	135,519	Dec 22 06:03 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 21 '23	Sale	85.21	79,684	6,789,874	55,835	Dec 22 06:03 PM
Gilliam Joseph E	PRESIDENT & COO	Dec 21 '23	Sale	84.80	25,000	2,120,062	120,001	Dec 22 06:05 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Dec 21 '23	Sale	85.14	583	49,637	55,242	Dec 22 06:04 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 15 '23	Option Exercise	7.28	60,000	436,500	115,835	Dec 18 08:39 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 15 '23	Sale	80.94	60,000	4,856,448	55,835	Dec 18 08:39 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Dec 15 '23	Sale	79.80	1,270	101,346	55,825	Dec 18 08:41 PM
Stapley Marc	Director	Dec 14 '23	Option Exercise	16.78	16,250	272,750	47,566	Dec 18 08:40 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 14 '23	Option Exercise	7.28	30,000	218,250	85,835	Dec 18 08:39 PM
Burns Thomas William	CHAIRMAN & CEO	Dec 14 '23	Sale	75.91	30,000	2,277,357	55,835	Dec 18 08:39 PM
Stapley Marc	Director	Dec 14 '23	Sale	75.93	16,250	1,233,875	31,316	Dec 18 08:40 PM
Burns Thomas William	CHAIRMAN & CEO	Oct 02 '23	Option Exercise	7.28	45,000	327,375	99,785	Oct 04 05:50 PM
Burns Thomas William	CHAIRMAN & CEO	Oct 02 '23	Sale	71.98	45,000	3,239,262	54,785	Oct 04 05:50 PM
Kliman Gilbert H	Director	Aug 04 '23	Option Exercise	7.28	10,000	72,750	39,725	Aug 08 04:54 PM
Kliman Gilbert H	Director	Aug 04 '23	Sale	74.56	10,000	745,600	29,725	Aug 08 04:54 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 19 '23	Option Exercise	7.28	200	1,455	674,163	Jul 21 04:23 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 19 '23	Sale	80.01	200	16,002	673,963	Jul 21 04:23 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 14 '23	Option Exercise	38.36	42,099	1,615,032	162,583	Jul 18 09:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 14 '23	Option Exercise	7.28	30,000	218,250	703,963	Jul 18 08:42 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 14 '23	Sale	78.34	42,099	3,298,036	120,484	Jul 18 09:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 14 '23	Sale	77.95	30,000	2,338,427	673,963	Jul 18 08:42 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 12 '23	Option Exercise	41.69	2,700	112,563	123,184	Jul 14 04:21 PM
Gilliam Joseph E	PRESIDENT & COO	Jul 12 '23	Sale	73.09	2,700	197,343	120,484	Jul 14 04:21 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 10 '23	Option Exercise	7.28	13,440	97,776	687,403	Jul 11 07:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 10 '23	Sale	70.87	13,440	952,480	673,963	Jul 11 07:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 07 '23	Option Exercise	7.28	133	968	674,096	Jul 11 07:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 07 '23	Sale	70.00	133	9,310	673,963	Jul 11 07:59 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 05 '23	Option Exercise	7.28	5,027	36,571	678,990	Jul 06 05:01 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 05 '23	Sale	70.02	5,027	351,991	673,963	Jul 06 05:01 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 03 '23	Option Exercise	7.28	26,400	192,060	700,363	Jul 06 05:01 PM
Burns Thomas William	CHAIRMAN & CEO	Jul 03 '23	Sale	69.51	26,400	1,835,041	673,963	Jul 06 05:01 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 28 '23	Option Exercise	7.28	26,810	195,043	700,773	Jun 30 06:01 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 28 '23	Sale	70.19	26,810	1,881,794	673,963	Jun 30 06:01 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 08 '23	Option Exercise	7.28	3,190	23,207	677,153	Jun 12 05:54 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 08 '23	Sale	70.02	3,190	223,364	673,963	Jun 12 05:54 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 07 '23	Option Exercise	7.28	17,382	126,454	691,345	Jun 08 06:30 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 07 '23	Sale	67.20	17,382	1,168,051	673,963	Jun 08 06:30 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 06 '23	Option Exercise	7.28	7,618	55,421	681,581	Jun 08 06:30 PM
Burns Thomas William	CHAIRMAN & CEO	Jun 06 '23	Sale	65.04	7,618	495,475	673,963	Jun 08 06:30 PM

Open in Screener

VCYT

Veracyte Inc

May 17 • 04:00PM ET

22.88

Dollar change -0.52
Percentage change -2.22	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI ARKG IWM VB VXF VBK IWN ARKW IBB

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	0.89%	Shs Outstand	76.45M	Perf Week	7.07%
Market Cap	1.75B	Forward P/E	239.06	EPS next Y	0.10	Insider Trans	-2.86%	Shs Float	75.77M	Perf Month	19.17%
Income	-68.18M	PEG	-	EPS next Q	-0.04	Inst Own	108.45%	Short Float	5.80%	Perf Quarter	-7.52%
Sales	375.47M	P/S	4.66	EPS this Y	89.22%	Inst Trans	0.35%	Short Ratio	6.01	Perf Half Y	-8.55%
Book/sh	14.64	P/B	1.56	EPS next Y	187.01%	ROA	-5.78%	Short Interest	4.39M	Perf Year	-8.70%
Cash/sh	2.74	P/C	8.36	EPS next 5Y	-	ROE	-6.20%	52W Range	18.61 - 30.52	Perf YTD	-16.83%
Dividend Est.	-	P/FCF	66.43	EPS past 5Y	-10.52%	ROI	-6.05%	52W High	-25.03%	Beta	1.73
Dividend TTM	-	Quick Ratio	4.69	Sales past 5Y	34.42%	Gross Margin	62.24%	52W Low	22.94%	ATR (14)	0.94
Dividend Ex-Date	-	Current Ratio	5.00	EPS Y/Y TTM	-122.18%	Oper. Margin	-1.42%	RSI (14)	62.66	Volatility	3.98% 4.31%
Employees	815	Debt/Eq	0.01	Sales Y/Y TTM	20.66%	Profit Margin	-18.16%	Recom	1.89	Target Price	29.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	77.79%	Payout	-	Rel Volume	0.86	Prev Close	23.40
Sales Surprise	3.74%	EPS Surprise	87.42%	Sales Q/Q	17.50%	Earnings	May 07 AMC	Avg Volume	730.26K	Price	22.88
SMA20	10.28%	SMA50	9.31%	SMA200	-3.73%	Trades		Volume	628,696	Change	-2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral
Aug-31-17	Resumed	BTIG Research	Buy	$13
Nov-14-16	Resumed	Leerink Partners	Outperform	$12
Dec-18-15	Initiated	Cantor Fitzgerald	Buy	$13
Jun-11-15	Reiterated	Leerink Partners	Outperform	$11 → $13

Show Previous Ratings

May-15-24 05:04PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-13-24 09:55AM	Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade (Zacks) +5.29%
May-08-24 03:13PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:55AM	Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View (Zacks)
07:12AM	Q1 2024 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:48AM	Loading…
03:48AM	Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ... (GuruFocus.com)
May-07-24 10:55PM	VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:13PM	Veracyte: Q1 Earnings Snapshot (Associated Press Finance)
06:00PM	Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test Performance (GuruFocus.com)
04:05PM	Veracyte Announces First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	14 Studies Presented at AUA 2024 Show Decipher Tests Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding (Business Wire)
Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
05:55PM	Loading…
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
08:30AM	Loading…
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Veracyte: Q2 Earnings Snapshot (AP Finance)
04:05PM	Veracyte Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 08:15AM	Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracytes Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Business Wire)
Jul-19-23 05:00PM	Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jun-20-23 08:31AM	New Data Suggest Veracytes Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer (Business Wire)
Jun-12-23 08:31AM	Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 (Business Wire)
May-30-23 06:56AM	Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-25-23 05:13PM	New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracytes Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer (Business Wire)
May-24-23 09:00AM	New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracytes Genomic Tests in Interstitial Lung Disease and Lung Cancer (Business Wire)
May-23-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-22-23 07:30AM	Here's Why This Little-Known Growth Stock Is a Buy (Motley Fool) +7.79%
May-12-23 06:15AM	Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Business Wire)
May-05-23 01:59PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 06:25PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Veracyte Announces First Quarter 2023 Financial Results (Business Wire)
09:45AM	New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules (Business Wire)
May-03-23 05:44PM	New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients (Business Wire)
08:30AM	Veracyte Announces Release of Inaugural ESG Report (Business Wire)
May-02-23 04:05PM	Data Published in "The Red Journal" Validate Clinical Utility of Veracytes Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer (Business Wire) -8.23%
May-01-23 05:35PM	Three Abstracts Focusing on the Clinical Utility of Veracytes Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference (Business Wire)
Apr-29-23 04:31PM	Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Apr-27-23 04:05PM	Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting (Business Wire)
10:02AM	Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Apr-18-23 09:48AM	The five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasing (Simply Wall St.)
Apr-17-23 08:30AM	New Data Reinforce Ability of Veracytes Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification (Business Wire)
Apr-13-23 05:00PM	Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 (Business Wire) +7.24%
Apr-12-23 08:30AM	Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting (Business Wire)
Mar-23-23 06:54AM	Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) (Simply Wall St.)
Mar-15-23 04:15PM	Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Companys Multi-Omics Capabilities and Tools for Biopharma Partners (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 12:11PM	Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank (Business Wire)
Mar-10-23 09:30AM	Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? (Motley Fool) -8.78%
Feb-27-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-23 05:42AM	We're Interested To See How Veracyte (NASDAQ:VCYT) Uses Its Cash Hoard To Grow (Simply Wall St.)
Feb-22-23 06:15PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.19%
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results (Business Wire)
Feb-15-23 08:36AM	Data Published in "The Red Journal" Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer (Business Wire)
Feb-13-23 05:23PM	New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment (Business Wire)
10:14AM	Stay Long and Strong: Billionaire Ken Fisher Snaps Up These 2 Strong Buy Stocks (TipRanks)
Feb-06-23 05:00PM	Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 (Business Wire)
Feb-01-23 04:05PM	Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Business Wire)
08:32AM	Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules (Business Wire)
Jan-24-23 10:23AM	Better Long-Term Buy in 2023: Exact Sciences or Veracyte? (Motley Fool)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire) +5.75%

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.17	3,090	93,232	35,173	Jul 24 05:06 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.14	838	25,257	37,601	Jul 24 05:06 PM
BISHOP JOHN L	Director	Jul 18 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
BISHOP JOHN L	Director	Jul 18 '23	Sale	30.50	10,000	305,000	33,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.19	7,441	224,616	38,263	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.16	2,324	70,090	38,439	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	23,949	720,106	45,704	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	19,095	574,106	40,763	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Sale	30.00	10,000	300,002	33,125	Jul 19 08:35 PM
Bhanji Muna	Director	Jun 16 '23	Sale	26.44	5,893	155,786	28,514	Jun 21 04:55 PM
Bhanji Muna	Director	May 30 '23	Sale	25.91	1,539	39,875	24,733	Jun 01 05:06 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

GKOS

Glaukos Corporation

VCYT

Veracyte Inc

Upgrade your FINVIZ experience